BioCentury | Dec 20, 2010
Clinical News

Oncopore: Phase I started

LTX-315 is in Phase I testing to treat solid tumors, while GV1001, a cancer vaccine targeting human telomerase reverse transcriptase (hTERT), is in Phase III testing to treat pancreatic cancer. Kael gained GV1001 through its...
BioCentury | May 31, 2010
Clinical News

Oncopore: Phase I started

Lytix began a European Phase I trial to evaluate injectable Oncopore in up to 40 patients with transdermally accessible solid tumors. Lytix Biopharma A/S , Tromso, Norway Product: Oncopore ( LTX-315 ) Business: Cancer Molecular target: NA Description:...
BioCentury | Dec 21, 2009
Clinical News

Oncopore: Phase I start

Lytix received approval in Norway and Sweden to begin an open-label, dose-ascending Phase I trial of Oncopore injection to treat cancer in up to 45 patients. 15 to 21 patients will be enrolled for the...
BioCentury | Jan 23, 2009
Financial News

Lytix raises $10.6 million

Lytix (Tromso, Norway) raised NOK73 million ($10.6 million) in a private round through an undisclosed group of new and existing investors. SpareBank Nord-Norge advised Lytix. The company plans to begin Phase I/II testing of two...
BioCentury | Aug 18, 2003
Company News

Spectral Genomics management update

Spectral Genomics Inc. , Houston, Texas Business: Diagnostics/Imaging Hired: Ed Chait as CEO, formerly CEO of PharmaCore Inc. WIR Staff Diagnostic...
BioCentury | Aug 11, 2003
Company News

Chait named CEO of Spectral Genomics

Ed Chait was named CEO of molecular diagnostics company Spectral Genomics (Houston, Texas). Prior to joining Spectral Genomics , Chait was CEO of small molecule drug discovery company PharmaCore (High Point, N.C.). BC Staff...
BioCentury | Mar 31, 2003
Company News

Pharmacor, Procyon deal

...7 million PBP shares valued at C$2.8 million based on PBP’s Friday close at C$0.40. Pharmacor...
...on its institutional holders investing C$3.2 million ($2.2 million) into PBP in a unit financing. Pharmacor...
...Solidarity Fund, have agreed to the acquisition. Pharmacor’s PL-100 protease inhibitor is in preclinical development. Pharmacor Inc....
BioCentury | Aug 29, 2002
Company News

Vicore Pharma names Kvarnstrom CEO

Vicore (formerly Pharmacore ) hired Ann-Christin Kvarnstrom as CEO. She was formerly VP of manufacturing strategy at AstraZeneca (AZN; LSE:AZN). Vicore is developing therapeutics for gastrointestinal and cardiovascular disorders. BC Staff...
BioCentury | Jul 29, 2002
Company News

De Novo Pharmaceuticals, GeneFormatics deal

The companies will research small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). Under the deal, GeneFormatics will use its proteomics technologies to identify all members of the M10 family in the human...
BioCentury | Jul 8, 2002
Company News

Pharmacor management update

Pharmacor Inc. , Montreal, Quebec Business: Chemistry Hired: Heimo Scheer as VP of regulatory and clinical strategic alliances, formerly director of regulatory and technical services at Quintiles Transnational Corp. WIR Staff...
Items per page:
1 - 10 of 21
BioCentury | Dec 20, 2010
Clinical News

Oncopore: Phase I started

LTX-315 is in Phase I testing to treat solid tumors, while GV1001, a cancer vaccine targeting human telomerase reverse transcriptase (hTERT), is in Phase III testing to treat pancreatic cancer. Kael gained GV1001 through its...
BioCentury | May 31, 2010
Clinical News

Oncopore: Phase I started

Lytix began a European Phase I trial to evaluate injectable Oncopore in up to 40 patients with transdermally accessible solid tumors. Lytix Biopharma A/S , Tromso, Norway Product: Oncopore ( LTX-315 ) Business: Cancer Molecular target: NA Description:...
BioCentury | Dec 21, 2009
Clinical News

Oncopore: Phase I start

Lytix received approval in Norway and Sweden to begin an open-label, dose-ascending Phase I trial of Oncopore injection to treat cancer in up to 45 patients. 15 to 21 patients will be enrolled for the...
BioCentury | Jan 23, 2009
Financial News

Lytix raises $10.6 million

Lytix (Tromso, Norway) raised NOK73 million ($10.6 million) in a private round through an undisclosed group of new and existing investors. SpareBank Nord-Norge advised Lytix. The company plans to begin Phase I/II testing of two...
BioCentury | Aug 18, 2003
Company News

Spectral Genomics management update

Spectral Genomics Inc. , Houston, Texas Business: Diagnostics/Imaging Hired: Ed Chait as CEO, formerly CEO of PharmaCore Inc. WIR Staff Diagnostic...
BioCentury | Aug 11, 2003
Company News

Chait named CEO of Spectral Genomics

Ed Chait was named CEO of molecular diagnostics company Spectral Genomics (Houston, Texas). Prior to joining Spectral Genomics , Chait was CEO of small molecule drug discovery company PharmaCore (High Point, N.C.). BC Staff...
BioCentury | Mar 31, 2003
Company News

Pharmacor, Procyon deal

...7 million PBP shares valued at C$2.8 million based on PBP’s Friday close at C$0.40. Pharmacor...
...on its institutional holders investing C$3.2 million ($2.2 million) into PBP in a unit financing. Pharmacor...
...Solidarity Fund, have agreed to the acquisition. Pharmacor’s PL-100 protease inhibitor is in preclinical development. Pharmacor Inc....
BioCentury | Aug 29, 2002
Company News

Vicore Pharma names Kvarnstrom CEO

Vicore (formerly Pharmacore ) hired Ann-Christin Kvarnstrom as CEO. She was formerly VP of manufacturing strategy at AstraZeneca (AZN; LSE:AZN). Vicore is developing therapeutics for gastrointestinal and cardiovascular disorders. BC Staff...
BioCentury | Jul 29, 2002
Company News

De Novo Pharmaceuticals, GeneFormatics deal

The companies will research small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). Under the deal, GeneFormatics will use its proteomics technologies to identify all members of the M10 family in the human...
BioCentury | Jul 8, 2002
Company News

Pharmacor management update

Pharmacor Inc. , Montreal, Quebec Business: Chemistry Hired: Heimo Scheer as VP of regulatory and clinical strategic alliances, formerly director of regulatory and technical services at Quintiles Transnational Corp. WIR Staff...
Items per page:
1 - 10 of 21